"COVID Testing is for ages 18 and up, with first symptom starting in past 5-6 days. Scheduled Appts Only, No Walk Ins (Due to supply chain) COVID Research Programs: Vaccine, Testing, Outpatient Treatment, and Household Prevention. No Costs, No Insurance, New Treatments, Possible Compensation"

During the past decade, Columbus Regional Research Institute conducted 93 clinical trials. In the 10-year time frame, 93 clinical trials started and 47 clinical trials were completed, i.e. on average, 50.5% percent of trials that started reached the finish line to date. In the past 5 years, 53 clinical trials started and 37 clinical trials were completed. i.e. 69.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Columbus Regional Research Institute" #1 sponsor was "Pfizer" with 15 trials, followed by "Eli Lilly and Company" with 7 trials sponsored, "ModernaTX, Inc." with 5 trials sponsored, "Allergan" with 4 trials sponsored and "Boehringer Ingelheim" with 4 trials sponsored. Other sponsors include 63 different institutions and companies that sponsored additional 55 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Columbus Regional Research Institute" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Medpace, Inc." with 3 trials as a collaborator, "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Dermira, Inc." with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Columbus Regional Research Institute" are "COVID-19" (5 trials), "Atopic Dermatitis" (4 trials), "Heart Failure" (4 trials), "Crohn Disease" (3 trials) and "Influenza, Human" (3 trials). Many other conditions were trialed in "Columbus Regional Research Institute" in a lesser frequency.

Most popular intervention types in "Columbus Regional Research Institute" are "Drug" (74 trials), "Biological" (18 trials), "Other" (12 trials), "Diagnostic Test" (4 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (49 trials), "Empagliflozin" (3 trials), "Lebrikizumab" (3 trials), "placebo" (3 trials) and "BNT162b2" (2 trials). Other intervention names were less common.

The vast majority of trials in "Columbus Regional Research Institute" are 96 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Columbus Regional Research Institute". undefined are not yet recruiting, 19 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 48 completed trials in Columbus Regional Research Institute, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Columbus Regional Research Institute, 9 "Phase 1" clinical trials were conducted, 40 "Phase 2" clinical trials and 50 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".